Vertex Pharmaceuticals Incorporated (VRTX) — Financial statements
Income statement, balance sheet, and cash flow for Vertex Pharmaceuticals Incorporated — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 12,075↑9.6% | 11,020↑11.7% | 9,869↑10.5% | 8,931↑17.9% | 7,574 | |
| Cost of Revenue | 1,807↑18.1% | 1,531↑21.3% | 1,262↑16.8% | 1,080↑19.5% | 904 | |
| Gross Profit | 10,268↑8.2% | 9,490↑10.3% | 8,607↑9.6% | 7,850↑17.7% | 6,670 | |
| Operating Expenses | ||||||
| R&D Expenses | 3,754↑3.4% | 3,630↑14.8% | 3,163↑19.1% | 2,656↓13.0% | 3,051 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 1,753↑19.7% | 1,464↑28.8% | 1,137↑20.3% | 945↑12.5% | 840 | |
| Other Expenses | 0.00↓100.0% | 4,628↑873.3% | 476↑927.0% | -58 | 0.00 | |
| Operating Expenses | 5,507↓43.4% | 9,723↑103.6% | 4,775↑34.8% | 3,543↓8.9% | 3,891 | |
| Total Costs & Expenses | 7,314↓35.0% | 11,253↑86.4% | 6,037↑30.6% | 4,623↓3.5% | 4,792 | |
| Operating Results | ||||||
| Operating Income | 4,761↑2144.1% | -233↓106.1% | 3,832↓11.0% | 4,307↑54.8% | 2,782 | |
| Depreciation & Amortization | 207↑0.7% | 206↑13.5% | 181↑22.3% | 148↑18.1% | 126 | |
| EBITDA | 4,968↑921.6% | 486↓89.4% | 4,605↑3.8% | 4,436↑52.0% | 2,918 | |
| EBIT | 4,761↑1605.7% | 279↓93.7% | 4,424↑3.2% | 4,287↑53.6% | 2,792 | |
| Interest & Other Income | ||||||
| Net Interest Income | 478↓15.8% | 568↓0.5% | 571↑535.4% | 90↑258.7% | -57 | |
| Interest Income | 491↓17.9% | 598↓2.7% | 615↑325.1% | 145↑2851.0% | 5 | |
| Interest Expense | 13↓56.5% | 31↓30.6% | 44↓19.5% | 55↓10.9% | 62 | |
| Non-Operating Income | 0.00↑100.0% | -512↑13.5% | -592↓3030.2% | 20↑306.1% | -10 | |
| Other Income / Expenses | -118↓124.4% | 481↓12.1% | 548↑830.4% | -75↓45.1% | -52 | |
| Income Before Tax | 4,643↑1768.5% | 249↓94.3% | 4,380↑3.5% | 4,232↑55.0% | 2,730 | |
| Income Tax Expense | 690↓12.0% | 784↑3.1% | 760↓16.5% | 910↑134.5% | 388 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 3,953↑838.1% | -536↓114.8% | 3,620↑9.0% | 3,322↑41.8% | 2,342 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 3,953↑838.1% | -536↓114.8% | 3,620↑9.0% | 3,322↑41.8% | 2,342 | |
| Bottom-Line Net Income | 3,953↑838.1% | -536↓114.8% | 3,620↑9.0% | 3,322↑41.8% | 2,342 | |
| EPS (Basic) | 15.46↑843.3% | -2.08↓114.8% | 14.05↑8.3% | 12.97↑42.7% | 9.09 | |
| EPS (Diluted) | 15.32↑836.5% | -2.08↓115.0% | 13.89↑8.3% | 12.82↑42.3% | 9.01 | |
| Weighted Average Shares | 256↓0.7% | 258↓0.1% | 258↑0.6% | 256↓0.6% | 258 | |
| Weighted Average Diluted Shares | 258↑0.0% | 258↓1.0% | 261↑0.5% | 259↓0.3% | 260 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.